Dataset Information

An updated perspective on deconvoluting chimeric MS/MS spectra by LC and precursor isolation and their subsequent assignment by the CharmeRT mPSM search strategy

ABSTRACT: Considering the recent advances in LC and mPSM methodologies, we aimed to provide a systematic comparison and in-depth analysis of the effects that standard and specialized LC setups, as well as different isolation windows, have on the occurrence and assignment of chimeric spectra derived from a complex peptide mixture. To this end, we provide a comprehensive analysis of how these factors influence the chromatographic resolution, isolation interference, and the subsequent identification of MS/MS spectra by a traditional or mPSM algorithm.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Permanent Cell Line Cell

SUBMITTER: Paul Abraham

LAB HEAD: Paul Abraham

PROVIDER: PXD012635 | Pride | 2019-05-20

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	11082018_easy_nlc_HELA_standard_2ug_500min_iw08_c18_HPLC_ac50cm_AP.msf	Msf
	11082018_easy_nlc_HELA_standard_2ug_500min_iw30_c18_HPLC_ac50cm_AP.msf	Msf
	20181019_HeLa_Std_2ug_2D_RP210_IW16_ENL_QE1_0_AP.msf	Msf
	20181019_HeLa_Std_2ug_Run2_2D_RP210_ENL_QE1_02.raw	Raw
	20181019_HeLa_Std_2ug_Run2_2D_RP210_ENL_QE1_02_CharmeRT_with_Model.msf	Msf

Items per page:

1 - 5 of 130

Similar Datasets

Project description:Objective: It has been suggested that patients' perception of treatment assignment might serve to bias results of double blind randomized controlled trials (RCT). Most previous evidence on the effects of patients' perceptions and the mechanisms influencing these perceptions relies on cross-sectional associations. This re-analysis of a double blind, placebo controlled RCT of pharmacological treatment of major depression set out to gather longitudinal evidence on the mechanism and effects of patients' perceived treatment assignment in the pharmacological treatment of major depression. Methods: One-hundred eighty-nine outpatients with DSM-IV diagnosed major depression were randomized to SAMe 1,600-3,200 mg/d, escitalopram 10-20 mg/days, or placebo for 12 weeks. Data on depressive symptoms (17-item Hamilton Depression Scale; HDRS-17), adverse events and patients' perceived treatment assignment was collected at baseline, week 6, and week 12. The re-analysis focused on N = 166 (out of the originally included 189 participants) with available data on perceived treatment assignment. Results: As in the parent trial, depressive symptoms (HDRS-17) significantly decreased over the course of 12 weeks and there was no difference between placebo, SAMe or escitalopram. A significant number of patients changed their perceptions about treatment assignment throughout the trial, especially between baseline and week 6. Improvement in depressive symptoms, but not adverse events significantly predicted perceived treatment assignment at week 6. In turn, perceived treatment assignment at week 6, but not actual treatment, predicted further improvement in depressive symptoms at week 12. Conclusions: The current results provide longitudinal evidence that patients' perception of treatment assignment systematically change despite a double blind procedure and in turn might trigger expectancy effects with the potential to bias the validity of an RCT. Parent study grant number: R01 AT001638 Parent study ClinicalTrials. gov Identifier: NCT00101452.

Dataset Information

An updated perspective on deconvoluting chimeric MS/MS spectra by LC and precursor isolation and their subsequent assignment by the CharmeRT mPSM search strategy

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets